Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor [21], has also been authorized in China for the management of HER2-positive ABC by PHEOBE and PHENIX trials [21,22], and recently approved for first line in advanced stages, based on efficacy and manageable toxicity in a randomized phase 3 PHILA trial [23]. Here, ERBB2 is linked to aneurysmal bone cyst.